Clinical Trial Update: 16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic Hemodialysis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for AKB-6548 in anemia associated with end-stage renal disease requiring hemodialysis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• End-stage Renal Disease

Drugs mentioned

• AKB-6548

Snippet

Sponsor: Akebia Therapeutics | Conditions: Anemia, End Stage Renal Disease | Phase 2 | Status: COMPLETED | Results posted: 2022-07-01